Tronics Hires Herve Borrel as Director of Sales and Marketing

GRENOBLE, France & MILPITAS, Calif.–(BUSINESS WIRE)–GRENOBLE, France, DALLAS, Texas, and MILPITAS, California, U.S.A. – May 24, 2011

Tronics, an international, full-service manufacturer of MEMS, today announced that industry veteran Hervé Borrel has been named director of sales and marketing.

Borrel, the former CEO of MicroChemical Systems, will guide expansion and growth of Tronics’ U.S. operations, including its high-volume MEMS foundry in Dallas and its medical division in California.

Borrel, who has more than 20 years of experience in semiconductors and MEMS for automotive and medical applications, led MicroChemical Systems (MiCS) from a startup to a recognized tier-one MEMS supplier for the automotive industry. Under his leadership, MiCS became a key supplier of MEMS gas sensors to many automakers and automotive equipment companies, including BMW, Volkswagen, General Motors, Volvo, PSA Peugeot Citroën, Hyundai, Valeo, Delphi, and Calsonic Kansei.

In 2007, Borrel sold MiCS to e2v Technologies, a British provider of subsystems and components for high-performance systems, and managed e2v’s Automotive Business Unit until the end of 2008.

Previously, Borrel worked for six years in the medical equipment industry, with Haemonetics Corp., including as general manager for the Benelux region. Prior to that he spent five years in the semiconductor industry working for Motorola.

“Hervé Borrel is an excellent fit for Tronics because of his broad experience in several of our key markets of medical devices, semiconductors and the automotive industry,” said Peter Pfluger, CEO of Tronics. “His proven success and expertise in these markets will enable him to play a leading role in our continued growth in North America.”

“I’ve watched Tronics over the years become a global leader in designing and manufacturing custom, high-performance MEMS for very demanding jobs in various industries,” said Borrel. “This opportunity to contribute to Tronics’ continued success – and its growth in the U.S. – was too good to pass up.”